On April 20, 2017 Genmab A/S (Nasdaq Copenhagen: GEN) reported that seven daratumumab abstracts have been accepted for presentation at the 2017 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago, June 2 — 6 (Press release, Genmab, APR 20, 2017, View Source [SID1234518646]). These abstracts, submitted by our collaboration partner, Janssen Biotech, Inc., include updates for the POLLUX and CASTOR trials, and the first data for a Phase I study evaluating daratumumab with carfilzomib, lenalidomide and dexamethasone in front line multiple myeloma patients, which will be presented in an oral presentation. In addition, descriptions of the Phase Ib/II study of daratumumab plus atezolizumab in non-small cell lung cancer and of our Phase I/II study with HuMax-AXL-ADC are scheduled for poster presentations at the meeting. The titles of the abstracts are currently available on the ASCO (Free ASCO Whitepaper) website with the full abstracts scheduled to be published on May 17, 2017.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are very pleased that, once again, a number of abstracts based on exciting work with Genmab’s innovative therapeutic antibody products have been accepted for presentation at the prestigious ASCO (Free ASCO Whitepaper) conference," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

List of abstracts:
Daratumumab:
Efficacy Of Daratumumab In Combination with Lenalidomide Plus Dexamethasone (DRd) or Bortezomib Plus Dexamethasone (DVd) in Relapsed or Refractory Multiple Myeloma Based on Cytogenic Risk Status — Oral presentation, Sunday, June 4, 11:45 AM — 11:57 AM CDT

Daratumumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma: An Open-Label, Phase Ib Study — Oral presentation, Sunday, June 4, 9:45 AM — 9:57 AM CDT

Safety and Efficacy of Daratumumab-based Regimens in Elderly (≥75 years) Patients with Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of POLLUX and CASTOR — Poster presentation, Monday, June 5, 8:00 AM — 11:30 AM CDT

Daratumumab, Lenalidomide and Dexamethasone (DRd) versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety Update (POLLUX) — Poster presentation, Monday, June 5, 8:00 AM — 11:30 AM CDT

Daratumumab, Bortezomib and Dexamethasone (DVd) versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety Update (CASTOR) — Poster presentation, Monday, June 5, 8:00 AM — 11:30 AM CDT

Randomized, Open-label Phase Ib/II Study of Atezolizumab with or without Daratumumab in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer — Trials in Progress Poster presentation, Saturday, June 3, 8:00 AM — 11:30 AM CDT

Comparative Efficacy of Multiple Myeloma Therapies for Treatment of First Relapse — A Systematic Literature Review and Network Meta-analysis — Poster presentation, Monday, June 5, 8:00 AM — 11:30 AM CDT

HuMax-AXL-ADC:
GCT1021-01, a First-in-Human, Open-Label, Dose-Escalation Trial with Expansion Cohorts to evaluate Safety of Axl-Specific Antibody-Drug Conjugate (HuMax-AXL-ADC) in Patients with Solid Tumors — Trials in Progress Poster presentation, Monday, June 5, 8:00 AM — 11:30 AM CDT